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Abstract
The FK506-binding protein 51 (FKBP51) is an Hsp90-associated co-chaperone which regulates steroid receptors and kinases.
In pancreatic cancer cell lines, FKBP51 was shown to recruit the phosphatase PHLPP to facilitate dephosphorylation of the
kinase Akt, which was associated with reduced chemoresistance. Here we show that in addition to FKBP51 several other
members of the FKBP family bind directly to Akt. FKBP51 can also form complexes with other AGC kinases and mapping
studies revealed that FKBP51 interacts with Akt via multiple domains independent of their activation or phosphorylation
status. The FKBP51-Akt1 interaction was not affected by FK506 analogs or Akt active site inhibitors, but was abolished by
the allosteric Akt inhibitor VIII. None of the FKBP51 inhibitors affected AktS473 phosphorylation or downstream targets of
Akt. In summary, we show that FKBP51 binds to Akt directly as well as via Hsp90. The FKBP51-Akt interaction is sensitive to
the conformation of Akt1, but does not depend on the FK506-binding pocket of FKBP51. Therefore, FKBP inhibitors are
unlikely to inhibit the Akt-FKBP-PHLPP network.
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Introduction
Akt (also called PKB) is a member of the serine-threonine kinase
AGC superfamily and has three isoforms (Akt1, Akt2, Akt3). It
constitutes an important node in diverse signaling cascades and
plays an essential role in cell survival, growth, migration,
proliferation, polarity, metabolism, and cell cycle progression
[1]. At the physiological level, Akt controls muscle and
cardiomyocyte contractility as well as angiogenesis. Because Akt
plays a crucial role in the phosphoinositide-3-kinase (PI3K)
pathway, which is frequently dysregulated in a wide variety of
cancers [2,3], Akt is a major target for cancer therapy [4]. The Akt
inhibitor perifosine is currently evaluated in phase III clinical trials
against various cancers whereas the allosteric Akt inhibitor MK-
2206 has reached phase I. To overcome the problem of feedback
regulation within the PI3K/Akt pathway dual PI3K/mTOR
inhibitors seem to be promising and several companies pursue
such compounds in phase I or phase II clinical trialsCourtney
et al. [5].
Akt is activated by binding of its N-terminal pleckstrin
homology (PH) domain to phosphatidylinositol 3,4,5-triphosphate
(PIP3), which affects the structure of Akt and recruits it to the
plasma membrane. Here, PDK1 phosphorylates the activation
loop (T308) and thereby activates Akt [6]. In addition, phosphor-
ylation of the hydrophobic motif (HM) at S473 by mTORC2 [7] is
a crucial step for maximal activation of Akt [8].Constitutive
phosphorylation on T450 occurs during translation and is required
for Akt stability [9]. Protein phosphatase PP2A has been shown to
dephosphorylate T308 and thereby inactivate Akt [10-11],
whereas PHLPP (PH domain leucine-rich repeat protein phos-
phatase) is a phosphatase known to inactivate Akt by dephos-
phorylation of S473 [12].
The hydrophobic motif (HM) is characteristic for most AGC
kinase family members, including serum- and glucocorticoid-
inducible kinase (SGK) and p70 ribosomal S6 kinase (S6K) [13].
The chaperone Hsp90 was shown to maintain stability of SGK
and Akt as well as several other kinases by direct interaction with
the kinase [14-15].The function of Hsp90 is fine-tuned by several
accessory cochaperones, including FKBP51 and FKBP52 [16].
They belong to the family of FK506-binding proteins (FKBPs),
which display peptidyl-prolyl-cis-trans isomerase (PPIase) activity
[17-18] In humans, at least 15 FKBPs have been identified [19].
The prototypical FKBP12 consists of only one FK506-binding
domain (FK1), which also displays the peptidyl-prolyl-cis-trans
isomerase activity. In complex with FKBPs, FK506 or rapamycin
induce inhibitory, ternary complexes with calcineurin and mTOR,
respectively [20]. FKBP51 consists of the N-terminal FK506-
binding domain (FK1) and an additional FKBP-like domain (FK2)
with high structural but modest sequence homology to the FK1
domainSchmidt et al. [21]. However, the FK2 domain has neither
PPIase activity nor binding affinity to immunosuppressants. At the
C-terminus, FKBP51 harbors a tetratricopeptide repeat domain
(TPR), where the Hsp90 interaction occurs [22].
Recently, FKBP51 was shown to act as a scaffold protein for the
phosphatase PHLPP, thereby negatively regulating the kinase Akt
[23]. In a pancreatic cancer xenograft model the positive
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chemotherapeutics was confirmed in vivo [24]. However, diverging
results have been reported from several other tumor tissues [25].
Nevertheless, the enhancement of the PHLPP-mediated Akt
dephosphorylation, e.g. via FKBP51, could be an option to
sensitize susceptible cancer cells to chemotherapy. However, to
implement this strategy pharmacologically, a much better bio-
chemical understanding of the Akt-FKBP51-PHLPP interaction is
required. The aim of our study was thus to get an improved insight
into the interaction of FKBP51 and Akt.
Results
Numerous FKBPs can Bind Directly to Akt
Since members of the FKBP family are highly homologous to
each other we asked if other FKBPs are able to bind to Akt.
Figure 1. Akt1 binds to several FKBPs and this interaction is direct. A HEK293T cells were transfected with HA_Akt1 and the indicated FKBP
constructs. After 2 days the lysates were immunoprecipitated (IP) and analyzed by Western blotting. B Purified FKBPs and purified GST-tagged
Akt1S473D (mimicking an active conformation) were subjected to a GST-pulldown followed by Western blotting. Cyclophilin, which also harbors
a TPR domain, but no FK domains, was used as a negative control. (Ld=Load, E=eluates). C Purified FLAG-tagged FKBP51 and purified inactive Akt
were mixed, subjected to a FLAG pulldown and analyzed by Western blotting.
doi:10.1371/journal.pone.0057508.g001
AKT-FKBP Interactions
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precipitated with FKBP52, FKBP25 and even with the smaller
FKBP12 and 12.6, which consist only of the FK506-binding
domain (Figure 1A). To examine whether these interactions are
direct, we used purified GST_Akt1
S473D [26], a GST-tagged
constitutively active Akt mutant, as well as purified FKBP
proteins [27] and performed pulldown assays (Figure. 1B). All
FKBPs bound to Akt1
S473D -loaded beads but not to empty
beads or beads loaded with GST alone (Figure S1). No
interaction was observed with purified Cyp40 [28], a closely
related immunophilin, which also has a TPR domain and binds
to Hsp90 but which lacks an FK506-binding domain. The
direct interaction with purified FKBP51 was confirmed in
a reversed pulldown using inactive untagged Akt1. Again, Akt1
was pulled down in the presence, but not the absence, of
FKBP51 (Figure 1C).
FKBP51 can Bind to Multiple AGC Kinases
It was shown that FKBP51 binds to Akt1 and Akt2 but not to
Akt3 [23]. To test whether the interaction of FKBP51 is specific to
Akt or whether other AGC kinases could also interact with
FKBP51 we performed co-immunoprecipitation experiments with
SGK and p70S6K. Both wildtype SGK and SGK harboring an
activating S422D mutation, clearly co-immunoprecipitated with
FKBP51 to a similar extent as GST-tagged Akt1 (Figure 2A).
FKBP51 and FKBP52 co-immunoprecipitated also with p70S6K
overexpressed in HeLa cells (Figure2B) while FKBP12 only
marginally bound to p70S6K.
Influence of the PH Domain of Akt and its
Phosphorylation Status on the Interaction with FKBP51
Next, we explored which domain of Akt is responsible for
binding to FKBP51. Therefore, we performed pull-down assays
with full length Akt and with an Akt construct lacking the PH
domain (Figure 3A). Both constructs interacted identically with
FKBP51 indicating that the PH domain is not necessary
(Figure 3B). This is consistent with the observed interaction of
FKBP51 with S6K and SGK, two kinases that lack the PH
domain. The conformation and activity of Akt1 is regulated by
phosphorylation at T308 and S473. To investigate the influence of
these important sites we performed immunoprecipitation assays
with HEK273T cell co-expressing FKBP51 (containing a TPR-
mutation to exclude confounding influences of Hsp90) together
with Akt1 containing a series of phosphorylation-resistant or
phosphomimetic substitutions at T308 and/or S473. All these Akt
constructs co-immunoprecipitated specifically with FKBP51 (TPR
mutant) but not with mock-transfected controls (Figure 3C and
Figure 3D). The phosphorylation status of T308 in the activation
loop of Akt was not important for the interaction with FKBP51
under these cellular conditions whereas the phosphoresistant
mutation S473A (lane 3 and 4) slightly increased binding of
FKBP51. We next controlled the Akt activation status by
stimulating or starving the cells or by inhibition of the PI3K
pathway using wortmannin (Figure 3E). As expected, starvation
(lane 2) and wortmannin treatment (lane 4) reduced phosphory-
lation of Akt at S473 and correlated with a slightly reduced
binding to FKBP51. The underlying reasons for discrepancy to the
results observed with the S473A mutant remain to be established.
Contrary to the findings by Pei et al. [23], we observed an increase
– not a reduction – in Akt S473 phosphorylation upon co-
expression of FKBP51.
Allosteric but not ATP-competitive Akt Inhibitors
Diminish the Interaction with FKBP51
Since Akt activation seemed to influence the interaction with
FKBP51 at least to a certain degree we next sought to control the
conformation of Akt more directly using Akt conformation-specific
inhibitors. We used a classical ATP-competitive inhibitor
(AT7867) (Figure 4A, lane 2), which binds and stabilizes the
activated ‘PH out’ conformation of Akt (PDB code 2UW9) [29] by
preventing access of phosphatases [30], and the allosteric inhibitor
(inhibitor VIII) (lane1), which intercalates between the PH and the
kinase domain of Akt and locks the latter in a closed inactive
conformation (PDB code 3O96) [31]. As expected, the ATP-
competitive inhibitor (AT7867) led to Akt hyperphosphorylation
[30,32] but it did not affect the interaction with FKBP51
(Figure 4A). This was confirmed in vitro by pulldown assays using
the non-hydrolyzable ATP analog AMP-PNP (Figure 4B). As
described, the allosteric inhibitor completely abolished cellular Akt
S473 phosphorylation [30,33]. Interestingly, this compound
substantially reduced binding of Akt to FKBP51. This suggests
that in the conformation stabilized by inhibitor VIII the binding
site with FKBP51 might be masked.
Multiple Domains of FKBP51 Contribute to the Binding to
Akt
We next aimed to map the domains of FKBP51 that interact
with Akt. First we truncated the FK506-binding domain (DFK1)
and the FK1-like domain (DFK1FK2) (Figure 5A). Both deletion
constructs co-immunoprecipitated with overexpressed Akt1
(Figure 5B). We also co-expressed Akt1 with two FKBP51 mutants
where the PPIase activity of the FK1 domain or the Hsp90-
Figure 2. Other AGC kinases can also bind to FKBP51. A
HEK293T cells were co-transfected in duplicates with GST-tagged Akt1
or DN_SGK
S422D and FLAG-tagged FKBP51. After 48 h, the lysates were
immunoprecipitated and analyzed in duplicates by Western blotting. B
HeLa cells were co-transfected with FLAG-tagged FKBPs and HA-tagged
S6K, treated with rapamycin (25 nM) or DMSO for 60 min and lysed.
Lysates were immunoprecipitated and analyzed by Western blotting.
doi:10.1371/journal.pone.0057508.g002
AKT-FKBP Interactions
PLOS ONE | www.plosone.org 3 February 2013 | Volume 8 | Issue 2 | e57508Figure 3. Influence of the PH domain and the activation status of Akt. A Domain structure of Akt B Purified GST-tagged active Akt or
a mutant lacking the PH domain were incubated with purified FLAG-tagged FKBP51. After 3 h, the interaction was tested by GST pulldown and
Western blotting. C and D HEK293T cells were transfected with the indicated HA-tagged Akt1 phosphorylation site mutants with or without co-
transfected FLAG-tagged FKBP51
K352A/R356A (TPR_mut). After 2 days cells were collected, lysed, immunoprecipitated and analyzed by Western
blotting (duplicates were analyzed for D). E HEK293T cells were starved for 16 h, stimulated with FCS for 45 min or treated with wortmannin. Controls
were incubated in the presence of 10% FCS and treated with DMSO. Cells were lysed, immunoprecipitated and analyzed by Western blotting.
doi:10.1371/journal.pone.0057508.g003
AKT-FKBP Interactions
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a construct lacking the putative C-terminal calmodulin- binding
site and the isolated FK506-binding domain (FK1). In all cases,
Akt1 co-immunoprecipitated with the FKBP51 constructs, al-
though with slightly reduced efficiency for the mutants (Figure 5C).
To confirm the capacity of multiple domains of FKBP51 to
interact with Akt we performed pulldown assays using purified
proteins (Figure 5D). The functionality of the FKBP51 proteins
(with exception of the FKBP51 DFK1 construct) was verified by an
active site titration for the FK506-binding pocket [27]. Again, all
FKBP51 constructs were retained by Akt1 to a similar extent. The
independence of the PPIase activity was further confirmed using
a pulldown assay with the isolated FK506-binding domain of
FKBP51 together with the corresponding PPIase-deficient mutant.
Both proteins bound to Akt to a similar extent (Figure 5E).
FKBP Inhibitors do not Disrupt FKBP-Akt Interaction
The ability of several FKBP members to bind to Akt (Figure 1)
suggested the FK506-binding pocket common to all these proteins
as an interaction site. We therefore tested if FKBP ligands blocking
the PPIase domain can reduce binding of Akt to FKBP51. We first
performed a pull-down experiment using purified FKBP51 and
purified AktS473D as bait in the absence and presence of the high-
affinity ligand rapamycin. The amount of FKBP51 that was
specifically retained by Akt was not affected by an excess of
rapamycin (Figure 6A). We next co-immunoprecipitated Akt with
FKBP51 or its TPR-mutant in the presence or absence of the non-
immunosuppressive FK506 analog FK1706 [34]. Binding of Akt
was slightly reduced for the TPR-mutant but it was still
significantly retained compared to background (Figure 6B). The
interaction with neither FKBP51 construct was affected by the
treatment with FK1706. Similar results were obtained in cells
treated with FK506 or rapamycin (Figure S2). Since PHLPP is
regulating Akt phosphorylation and is proposed to be part of the
Akt-FKBP51-PHLPP complex [23] we explored whether FKBP
inhibitors affected the FKBP51-PHLPP complex. FKBP inhibitors
had no effect on the integrity of the complex of FKBP51 with
PHLPP1 or PHLPP2 (Figure 6C, Figure 6D). Finally, we tested
whether cellular Akt or mTOR phosphorylation would be affected
by FKBP inhibitors. Neither the phosphorylation of Akt at T308
nor S473 was affected in HEK293T cells treated with high
concentrations of FK1706. Under the same conditions the mTOR
inhibitor Torin-1 reduced Akt phosphorylation at both sites [35],
while the ATP-competitive inhibitor AT7867 enhanced it
demonstrating that the assay was able to detect the dynamic
regulation of Akt in these cells (Figure 6E). Similar results were
obtained for Akt S473 and mTOR S2448 phosphorylation in
FK1706 or FK506-treated SHSY-5Y (Figure 6F) and HeLa cells
(Figure S3). Rapamycin which served as control stimulated and
inhibited both phosphorylations in the expected way. Since
FKBP51 was shown to regulate the sensitivity of pancreatic
cancer cells to chemotherapeutics [23,24] we tested the effect of
FKBP inhibitors in these cells. In a cell viability assay we observed
that FK1706 (10 mM) did not enhance the cytotoxic effect of
Gemcitabine in SU.86.86 cells (Figure 6G).
Discussion
The kinase Akt is a key signaling node which is essential for
many adaptive processes (e.g., neuroregeneration [36], but
detrimental when overactive like in many cancers. In turn, the
activity of Akt is tightly regulated under normal conditions.
Recently, FKBP51 emerged as a new regulator of Akt. FKBP51 is
a Hsp90-cochaperone and a target of the clinically used
immunosuppressants or anticancer-drugs FK506 and rapamycin
[37]. While the role of protein kinases in cancer development is
well established, the influence of FKBP51 on malignancy is
contradictory. Several studies have shown that FKBP51 is up-
regulated in several cancers and that it can promote the
proliferation of many cancer cell lines [25,38-41]. In contrast,
Wang and colleagues found FKBP51 to enhance the response to
chemotherapeutics, such as Gemcitabine in pancreatic and breast
cancer cell lines [23,24]. Mechanistically, the latter effect was
attributed to a scaffolding function of FKBP51, which could
promote dephosphorylation of Akt by the phosphatase PHLPP.
However, the exact interaction mode of FKBP51 with AKT and
PHLLP is not known.
Our study supports a robust FKBP51-Akt1 interaction but we
were unable to observe enhanced dephosphorylation upon
FKBP51 expression. This could be due to PHLPP not being the
rate-limiting phosphatase for Akt in our cells and under our cell
culture conditions. According to our results the interaction of Akt
and FKBP51 might be more complex than previously thought
(Figure 7).
First, the interaction is not restricted to FKBP51 since Akt can
bind to several FKBPs. Whether different FKBPs can compete for
a similar binding site on Akt and whether this could be important
for the effect of individual FKBPs on Akt remains to be
Figure 4. The FKBP51-Akt interaction depends on the confor-
mation of Akt. A HEK293T cells were transfected with FLAG-tagged
FKBP51
K352A/R356A (TPR_mut) and HA-tagged Akt1. After 2 days cells
were treated with 10 mM inhibitor VIII, AT7867 or DMSO for 1 h. Cell
lysates and immunoprecipitates were analyzed in duplicates by Western
blotting. B GSH beads loaded with purified activated GST_Akt1DPH
were incubated with FKBP51 with or without AMP-PNP. Eluates were
analyzed by Western blotting.
doi:10.1371/journal.pone.0057508.g004
AKT-FKBP Interactions
PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e57508Figure 5. Mapping of the FKBP51 domains interacting with Akt. A Left: Overview of the constructs used to map the FKBP51/Akt interaction.
Right: Summary of the Akt interactions of FKBP domains investigated in HEK293T cells by immunoprecipitation or by pulldown with purified
proteins. (WT=wildtype). B and C HEK293T cells were transfected with the indicated constructs. After 48 h, lysates were prepared and HA- or FLAG-
immunoprecipitation was performed, followed by Western blotting. D GSH beads loaded with purified GST-tagged Akt1
S473D were incubated with
the indicated FLAG-tagged FKBP51 mutants for 3 h. After elution a Western blot analysis was performed. E GSH beads loaded with purified GST-
tagged Akt1
S473D were incubated with the indicated FLAG-tagged FKBP51FK1 constructs for 3 h. After elution a Western blot analysis was performed
and the detected with an antibody which detects the FK1 domain of FKBP51.
doi:10.1371/journal.pone.0057508.g005
AKT-FKBP Interactions
PLOS ONE | www.plosone.org 6 February 2013 | Volume 8 | Issue 2 | e57508AKT-FKBP Interactions
PLOS ONE | www.plosone.org 7 February 2013 | Volume 8 | Issue 2 | e57508established. For example, other FKBPs could displace FKBP51
from the Akt-PHLPP complex in a way reminiscent of the
opposing effects of FKBP51 and FKBP52 on steroid hormone
receptors [20] (Figure 7A).
Second, FKBP51 can interact with several AGC kinases in
addition to Akt. Similarly, kinases from other classes have
previously been reported to bind to FKBP51 [30,42,43]. The
signaling of Akt, SGK and S6K is highly interconnected. Any
effects observed on the PI3K-Akt-mTOR pathway after FKBP51
overexpression or downregulation are thus not necessarily being
mediated via Akt but could be due to modulation of any of those
kinases. Whether the binding to SGK or S6K is direct or via a third
partner (e.g., Hsp90) is currently unclear (Figure 7B).
The PH domain itself is not required for the FKBP51-Akt
interaction and is absent in other protein kinases that are also
interaction partners of FKBP51. The best indication where
FKBP51 binds on the Akt surface was obtained using the
conformation-specific Akt inhibitors. The structures of Akt in
complex with AT7867 and inhibitor VIII show that most of the
core C- and N-lobes are structurally conserved, indicating that
most regions of the conserved kinase domain may not provide the
key interaction sites with FKBP51. The most prominent difference
Figure 6. Influence of FKBP inhibitors. A Purified proteins were mixed and treated with DMSO or rapamycin (1 mM). After 3 h a GST-pull-down
was performed followed by Western blotting. B HEK293T cells were transfected with the indicated constructs. After 48 h 1 mM FK1706 was added for
1 h. The lysates were immunoprecipitated and a Western blot was performed. C and D HEK293T cells were transfected with FLAG-FKBP51 and HA-
tagged PHLPP1 or HA-tagged PHLPP2. After 48 hFKBP inhibitors (1 mM) or DMSO were added for 1h. Lysates were immunoprecipitated and analyzed
by Western blotting. E HEK293T cells were stimulated with FCS for 1 h in the presence of the indicated compounds. After cell lysis, cellular Akt
phosphorylation was determined using a homogeneous time- resolved FRET assay. F SHSY-5Y cells were stimulated with FCS for 1 h in the presence
of the indicated compounds. After cell lysis, cellular Akt and mTOR phosphorylation was determined using a homogeneous time resolved FRET assay.
G SU.86.86 cells were plated, treated with Gemcitabine in the absence or presence of FK1706. Cell survival relative to DMSO treated controls was
determined.
doi:10.1371/journal.pone.0057508.g006
Figure 7. Schematic model of possible Hsp90-Akt-FKBP51 complexes. A FKBP51 can bind directly to Akt via its FK1 domain, but not with its
FK506-binding pocket. Several other FK1-possessing FKBP homologs may bind to Akt in a similar mode. B Akt and several other kinases can bind to
FKBP51 indirectly via Hsp90. C FKBP51 could assist the chaperoning of Akt by binding to Hsp90 via its TPR domain and by interacting with Akt via its
FK1 domain.
doi:10.1371/journal.pone.0057508.g007
AKT-FKBP Interactions
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VIII is the rearrangement of the aC-helix (residues 185–205),
which is stabilized in the presence of AT7867 allowing the binding
of the HM to the PIF-pocket and destabilized in complex with
inhibitor VIII. In addition, the activation loop (residues 292–313)
is completely occluded by the PH domain in the presence of
inhibitor VIII. Interestingly, the attachment of the PH domain to
the catalytic domain of Akt occluding the activation loop, as
observed in complex with inhibitor VIII, is thought to occur in the
inactive conformation of Akt [44,45], to which FKBP51 also
binds. Therefore, a key binding site for FKBP51 is unlikely to lie
within the PH-domain interaction site on the catalytic domain.
Rather, the interaction site may exist at or within the proximity of
the actual site where inhibitor VIII binds on the catalytic domain
or at allosteric sites affected by the interaction with inhibitor VIII.
Interestingly, the binding of inhibitor VIII to Akt completely
disrupts the formation of the aC-helix highlighting this region,
which appears highly flexible in AGC kinases in solution, as the
potential common recognition site for kinases by FKBPs.
Third, the Akt-FKBP51 interaction is probably bimodal at the
biochemical level (Figure 7C). Binding of Akt to FKBP51 is
mediated in part by Hsp90 since it is partially affected by Hsp90-
disrupting mutations. However, FKBP51 can clearly bind to Akt
also directly via the FK1 domain. This is consistent with the
domain mapping of FKBP51 where all constructs that contained
either a functional TPR (Figure 5B–D) domain or the FK1
domain (Figure 5E) were able to bind to Akt. The only exception is
the pull-down of purified FKBP51 D FK1_FLAG, where FKBP51
lacks the FK1 domain and cannot bind via Hsp90 since the latter
is lacking in the purified reconstituted system. This may indicate
that FKBP51 can bind to Akt also via the FK2 domain or it could
be due to misfolding of this construct and spurious binding of Akt
(DFKBP51 FK1_FLAG was the only construct that could not be
checked by active site titration prior to the pull-down assays). The
two-domain interaction model also raises the possibility that
FKBP51 might use both interaction sites to regulate Akt within
a FKBP51-Hsp90-Akt complex, similar to the putative regulation
of steroid hormone receptors by FKBP51.
All FKBPs contain a highly conserved FK506 binding site,
which displays the PPIase activity but which can also mediate
protein-protein interactions [46]. The finding that all FKBPs, but
not Cyp40, bound to Akt strongly suggested the common FK506-
binding site as the connector to Akt. However, binding of FKBP51
to Akt was not affected by several high-affinity ligands, neither in
purified systems nor in cells were the alternative binding mode via
Hsp90 was controlled for. Likewise, mutations in the FK506-
binding site, which abolish the PPIase activity, did not affect
binding to Akt. This suggests that other parts of the FK1 domain
of FKBP51 interacted with Akt. While other parts of the FK506-
binding domain are less conserved between the different FKBP
homologs they still share a highly conserved structural fold [47],
which could be important for binding to Akt.
The inability of FKBP51 ligands to disrupt the FKBP51-Akt
interaction suggests that the clinically used FKBP ligands are
unlikely to affect the regulation of Akt by FKBP51. This is
consistent with the lack of an effect of the high-affinity ligands
FK506 or FK1706 on the Akt-mTOR pathway in several studied
cell types. Likewise, the sensitivity towards cytostatic agents, which
was reported to be suppressed by FKBP51 [23],[24], was not
affected by FK1706. At the biochemical level, however, parts of
the FK1 domain, which must be in the vicinity of the FK506-
binding site, seem to be important for the interaction with Akt.
This raises the possibility to develop ligands for the FK506-binding
site that might be able to allosterically modulate the FKBP51-Akt
interaction. The feasibility of this hypothesis will require a better
understanding of the parts of FKBP51 that bind to Akt.
Materials and Methods
Plasmids and other Materials
The pcDNA3 constructs for expression in mammalian cells
were generated using the primer pairs 59-CGGAATTCATG-
GACTACAAGGACGATGACGATAAGATGGGAGTG-
CAGGTGGAAACCATC-39 and 59-GG CTCGAGTCATTC-
CAGTTTTAGAAGCTCCACA-39 (FKBP12_FLAG)
59CGGAATTCATGGACTAC AAGGACGATGACGATAA-
GATGGGCGTGGAGATCGAGACCATC-39 and 59-
GGCTCGAGTCACTCTAAGTTGAGCAGCTCC-39
(FKBP12.6_FLAG) 59-CGGAATTCATGGACTAC AAGGAC-
GATGACGATAAGATGGCGGCGGCCGTTCCACAGCGG-
39 and 59-GG CTCGAG TCAATCAATATCCACTAATTC-
CACTT-39 (FKBP25_FLAG), 59-CGGAATTCATGACTACT-
GATGAAGGTGC-39 and 59-GCAGTCGACTCTCCTTT-
GAAATCAAGGAGC –39 (FKBP51_FLAG) 59-
CCGAATTCATGACAGCCGAGGAGATG-39 and 59-
GTCGACTCATTCTCCCTTAAACTCAAACAACTC-39
(FKBP52_FLAG) 59-ACCAGGTACCATGTTTGAAGATG-
GAGGCATTATCCG-39 and 59-TTTTTTGAATTCT-
CACTTGTCATCGTCGTCCTTGTAGTC-39
(FKBP51DFK1_FLAG), 59-CCGAGGTACCATGGATAC-
CAAAGAAAAATTGGAGCAG-39 59-TTTTTTGAATTCT-
CACTTGTCATCGTCGTCCTTGTAGTC-39
(FKBP51DFK1FK2_FLAG).
The amplified cDNA was cloned into the pcDNA3 vector using
the restriction sites EcoRI and Xho, XbaI and KpnI or KpNI and
EcoRI. pRK5 constructs were a kind gift of Dr. Theo Rein (MPI
for Psychiatry, Munich, Germany) [48].
His-tagged full length FKBPs and Cyp40 were expressed as
described [27,28]. pProExHta_DFK1 was generated using the
primers 59-GGGAGAATTCTTTGAAGATGGAGGCAT-
TATCCG-39 and 59-TACCTCATACGTGGCCCT-
CAGGTTTCTC-39. pProEx-Hta_FK1 was generated using the
primers 59- CATGCCATGGCAATGACTACTGATG-39 and
59-CAGTCGACTCACTCTCCTTTGAAATCAAGGAGC-39.
The constructs were cloned into pProExHta at the restriction sites
EcoRI/KpNI and NcoI/SalI, respectively. Point mutations were
obtained with the QuikChangeIIH Site-Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, CA).
pCMV5.HA_Akt1WT, pCMV5.HA_Akt1
S473A,
pCMV5.HA_Akt1T
308D/S473D plasmids were a kind gift of Dr.
Brian Hemmings and Dr. Peter Cron (FMI, Basel, Switzerland).
pEBG2T-Akt1DPH, pEBG2T-DNSGK and pEBG2T-
DNSGK
S422D were desribed before [26]. pcDNA3-HA-PHLPP1
(Plasmid #22404), pcDNA3-HA-PHLPP2(Plasmid #22403) and
pRK7-HA-S6K1 were purchased from Addgene (Plasmid #8984).
Purified inactive Akt1 as well as wortmannin and inhibitor VIII
were purchased from Merck Millipore, Billerica, MA.
All cell culture media (DMEM, D-PBS, foetal bovine serum
(FBS), penicillin/streptomycin) were purchased from Gibco-
Invitrogen (Carlsbad, CA). Rapamycin was bought from Cfm
Oscar Tropitzsch (Marktredwitz, Germany) and FK1706 was
a kind gift from Astellas Pharma Inc. (Tokyo, Japan). Inhibitor
AT7867 was acquired from Selleckchem (Houston, TX). FK506,
AMP-PNP and protease inhibitors were purchased from Sigma-
Aldrich (Steinheim, Germany).
The antibodies against FKBP12, FKB12.6 and FKBP25 and ß-
Actin were obtained from Abcam (Cambridge, UK). Antibodies
against AktpS473 and Akt (pan) were purchased from Cell
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FKBP52 were purchased from Bethyl Laboratories (Montgomery,
AL). Antibodies against Cyp40 and Hsp90 were provided by Santa
Cruz Biotechnology (Santa Cruz, CA). The antibody against the
FK1 domain (FFI) was a kind gift of M. Cox [49]. Nickel-NTA
agarose was from Qiagen (Hilden, Germany).
GST Pulldown Assay
15 mM FKBPs or Cyp40 were combined with 22 mM
GST_Akt1
S473D or GST_Akt1
S473D_DPH coupled to 10 ml
glutathion resin (Miltenyi Biotech, Bergisch Gladbach, Germany)
and incubated for 3 h in 500 ml NETN buffer (20 mM Tris-HCl
[pH 8.0], 100 mM NaCl, 1 mM EDTA, 0.5% igepal, 50 mM
glycerophosphate and 10 mM NaF, 0,5 mM natriumdihydrogen-
orthovanadat) at 4uC. AMP-PNP (5 mM), rapamycin (1 mM) or
DMSO were added where indicated. After 3 h the resin was
collected, washed 5 times with each 1 ml NETN buffer and finally
boiled in 20 ml SDS sample buffer. The supernatant was subjected
to SDS gel electrophoresis and immunoblotting.
FLAG Pulldown Assay
10 ml FLAG column saturated with FKBP51_FLAG was
incubated with 20 mM inactive Akt (Millipore) in 500 ml NETN
buffer at 4uC overnight. The next day the resin was collected,
washed 5 times with NETN buffer and eluted with FLAG peptide
according to the manufacturer’s instruction. The elution was
subjected to SDS-PAGE and immunoblotting.
Cell Culture and Transfection
HEK-293T cells were maintained in DMEM, supplemented
with 10% FBS and 1% antibiotics (penicillin, streptomycin)
solution. For transfection, cells were plated in 6-well plates and
subjected to Lipofectamine 2000 transfection procedure as
recommended by the manufacturer (Invitrogen). Compounds
were added where indicated to the culture medium (Inhibitor VIII
or AT7867, each 10 mM, 1 h), FK506, rapamycin or FK1706
(each 1 mM, 1 h), wortmannin (200 nM, 6 h). Cells were starved
in FCS free medium for 16 h and stimulated with FCS (30 min)
when indicated.
Cell Lysis and Immunoprecipitation
After stimulation and/or treatment with the indicated com-
pounds cells were washed twice with PBS and lysed in NETN
buffer containing 1% (v/v) protease inhibitor mix (Sigma-Aldrich)
and PMSF (1 mM) (Carl Roth, Karlsruhe, Germany) by shaking
at 1000 rpm at 4uC. After 20 min the supernatant was collected
by centrifugation 4uC at 14.000 rpm. Total protein was de-
termined by BCA Assay (Thermo Fisher Scientific, Rockford, IL).
Cell lysates were combined with FLAG or HA affinity resin and
incubated under moderate agitation overnight at 4uC. Beads were
pelleted or collected with the magnet and washed 5 times with lysis
buffer. Finally, beads were directly boiled after addition of an
equal amount of SDS sample buffer for 5 min and SDS-Page
followed by immunoblotting was performed.
In vivo Phosphorylation Assays for Akt and mTOR
Phosphorylation at Akt(S473), Akt(T308) and mTOR(S2448)
was assessed using a homogeneous time-resolved fluorescence
assay (Cisbio, Codolet, France) according to the manufacturer’s
recommendations. Briefly, HEK293, SH-SY5Y or HeLa cells
were grown in 96-well plates in FCS in the presence of 10 mM
FKBP ligand or 100 nM torin-1 for 60 min. Cells were lysed and
the lysates were transferred to a white 384-well plate. After
addition of d2-labeled anti-Akt or anti-mTOR antibody and K-
labeled anti-phospho-Akt or anti-phospho mTOR antibody, the
mixtures were incubated at room temperature for 4 h or
overnight. FRET efficiency was determined by the emission ratios
665 nm/620 nm after excitation at 320 nm using a Tecan
GENios Pro reader. The data were normalized to the results for
Torin-1 (0%) and DMSO (100%).
Cell Viability Assay
Cell viability of SU.86.86 cells treated with gemcitabine or
gemcitabine with additional FK1706 was assessed using the
CellTiter-Fluor Cell Viability assay from Promega, Madison, WI
according to the manufacturer’s protocol. Briefly, cells were plated
into a 96-well plate and treated with gemcitabine (0,126 nM-
5 mM) or gemcitabine+FK1706 (10 mM) for 72 h. Thereafter,
CellTiter-Fluor reagent was added and cells were incubated at
37uC for 30 min. Fluorescence was measured at an excitation of
370 nm and an emission of 520 nm using a Tecan GENios Pro
reader. DMSO treated cells served as control and were correlated
with treated cells.
Supporting Information
Figure S1 HEK293T transfected with the indicated
constructs were treated with or without 1 mM FK506 or
rapamycin 1 mM for 1 h followed by immunoprecipita-
tion and western blotting.
(TIFF)
Figure S2 GST protein and GST_Akt
S473DDPH were
coupled to GSH beads. Beads were incubated for 3 h
with FKBP51_FLAG and eluted with GSH followed by
western blotting.
(TIFF)
Figure S3 HeLa cells were stimulated with FCS for 1 h
in the presence of the indicated compounds. After cell
lysis, cellular Akt and mTOR phosphorylation was determined
using a homogeneous time- resolved FRET assay.
(TIFF)
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